Doxazosin 2mg tab 30 pcs ozone

Description

Composition
Active substance:
1 mg 1 tablet: doxazosin mesylate – 1.21 mg, in terms of doxazosin – 1.00 mg. 2 mg 1 tablet: doxazosin mesylate – 2.43 mg, in terms of doxazosin – 2.00 mg. 1 tablet 4 mg: doxazosin mesylate – 4.85 mg, in terms of doxazosin – 4.00 mg.
Product form:
Tablets 1 mg, 2 mg, 4 mg. At 5, 10, 15, 20 or 30 tablets in blisters of PVC film and aluminum foil printed patent. 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 tablets in cans or in cans PET polymer for medicaments. One jar or 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 contour of cellular packaging together with instructions for use placed in a cardboard box (pack).
Contraindications
Hypersensitivity to doxazosin, other quinazoline derivatives (including for prazosin, terazosin) or any of the auxiliary components of the drug, the other alpha-adrenergic blockers; orthostatic hypotension (including history), chronic urinary tract infections, urolithiasis, anuria, urinary obstruction related, progressive renal failure; severe liver failure (insufficient experience application); breastfeeding (for the treatment of hypertension), age 18 years (effectiveness and safety have been established); lactose intolerance, lactase deficiency and syndrome of glucose-galactose malabsorption. Additionally, as indicated in the treatment of symptomatic treatment of BPH: urinary incontinence due to overflow of the bladder, hypotension.
Dosage
2 mg
Indications
• Benign prostatic hyperplasia: both in the presence of hypertension and with normal blood pressure. • Hypertension: in combination with other antihypertensive agents (thiazide diuretics, beta-blockers, blockers “slow” calcium channels or angiotensin converting enzyme (ACE) inhibitors).
pharmachologic effect
Pharmacological group:
Alpha1-blocker. ATC code S02SA04.
Pharmacological properties:
Benign prostatic hyperplasia Assignment doxazosin in patients with symptomatic benign prostatic hyperplasia (BPH) leads to a significant improvement in performance and reduction urodynamics manifestations of disease symptoms. This action of the drug associated with the selective blockade of alpha-adrenoreceptors located in the stroma and prostatic capsule and bladder neck. It is proved that the blocker is doxazosin, an alpha 1-adrenoceptor subtype 1A, which constitute about 70% of all subtypes of the alpha-1 adrenergic receptors present in prostate. This explains its action in patients with BPH. Supportive treatment effect of doxazosin and its proven safety of long-term use of the drug (e.g., up to 48 months). Hypertension The use of doxazosin in hypertensive patients results in a significant decrease in blood pressure (BP) by decreasing total peripheral vascular resistance. The appearance of this effect is attributed to the selective blockade of alpha1-adrenoceptors located in the vascular network. Before the drug once a day 1 clinically significant antihypertensive effect lasts for 24 hours, blood pressure is reduced gradually; maximal effect is usually observed after 2-6 hours after ingestion of the drug. In patients with hypertensive blood pressure during treatment with doxazosin was similar in position “lying” and “standing”. It is noted that in contrast to the non-selective alpha1-adrenergic blockers in long-term treatment with doxazosin tolerance to the drug did not develop. When carrying out maintenance therapy increase in plasma renin activity of blood and tachycardia are rare. Doxazosin has a beneficial effect on blood lipid profile, increasing the ratio of high density lipoprotein cholesterol concentration to the total cholesterol concentration and significantly reducing overall triglyceride and total cholesterol. In this regard, he has an advantage over diuretics and beta-blockers, which are not affected favorably on these parameters. Given the established relationship of hypertension and blood lipid profile with coronary heart disease, normalization of blood pressure and lipid concentrations in patients receiving doxazosin lead to a reduction in the risk of coronary heart disease. It has been observed that treatment of doxazosin resulted in the regression of left ventricular hypertrophy, inhibition of platelet aggregation, and enhance the activity of tissue plasminogen activator. Furthermore, it was found that doxazosin improves insulin sensitivity in patients with impaired glucose tolerance. Doxazosin has no adverse metabolic effects and can be used in patients with asthma, diabetes, left ventricular failure and gout. Studies in vitro have shown antioxidant properties and 7 ‘, 6` gidroksimetabolitov doxazosin in a concentration of 5 micromolar. In controlled clinical trials conducted in hypertensive patients, doxazosin treatment was associated with improvement of erectile function. In addition, patients treated with doxazosin, the newly emerged erectile dysfunction were observed less frequently than in patients treated with antihypertensive drugs.
Conditions of supply of pharmacies
Prescription.
Dosing and Administration
Doxazosin drug can be administered in the morning and evening, and is intended for oral administration. 1 is taken once a day, regardless of the meal. The tablet must be swallowed without chewing, with a sufficient amount of water. Benign prostatic hyperplasia recommended starting dose of the drug doxazosin is 1 mg 1 time per day in order to minimize the possibility of orthostatic hypotension and / or syncope. Depending on the individual characteristics and availability urodynamics indices BPH symptoms the dose can be increased to 2 mg, and later 4 mg and up to a maximum daily dose of 8 mg. The recommended dose range for the increase of 1 -2 weeks. Usually the recommended maintenance dose is 1 mg 2-4 times a day. Hypertension The dosage varies from 1 to 16 mg / day. Treatment is recommended to start with an initial dose of 1 mg 1 time per day at bedtime. After the first dose, the patient must stay in bed for 6-8 hours. This is required in connection with the development of the phenomenon of “first dose” is particularly pronounced on the background of the previous diuretics. When insufficient therapeutic effect of the daily dose can be increased to 2 mg every 1-2 weeks. Subsequently, every 1 – 2 weeks of dose can be increased to 2 mg. The vast majority of patients the optimal therapeutic effect is achieved at a dose of 8 mg per day. The maximum daily dose of 16 mg per day may not be exceeded. After reaching a stable therapeutic effect dose is generally reduced (the average therapeutic dose for maintenance therapy is typically 2-4 mg per day). If therapy is added to a diuretic or other antihypertensive agent, doxazosin is necessary to adjust the dose depending on the patient’s condition with further titration under a physician’s supervision. In elderly patients and patients with impaired renal function is recommended to appoint Doxazosin in normal doses. Patients with impaired liver function requires careful selection of doses. Clinical data on the use of the drug Doxazosin in patients with severe hepatic impairment is not enough.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist